1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Technology appraisal guidance [TA170] Published: 22 April 2009

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • Appendix A: Appraisal Committee members, guideline representatives and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

1 Guidance

1 Guidance

1.1 Rivaroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery.

  • National Institute for Health and Care Excellence (NICE)

  • Next